Key result
COVID-19 mRNA vaccine linked to acute myocarditis three days post-vaccination in a 25-year-old male.
Why the study?
This case report was conducted to further investigate the association between mRNA-derived COVID-19 vaccination and subsequent acute myocarditis development.
Case Report (n=1)
No
This case report highlights a potential rare adverse event of acute myocarditis following the second dose of a COVID-19 mRNA vaccine in a young adult.
Answers are grounded in this paper and cite their sources.
Supports vigilance for myocarditis after mRNA vaccination; leaves open incidence and causality.
The mRNA vaccines for coronavirus disease-2019 (COVID-19) have been implemented across the globe for both emergent and non-emergent applications. We present a rare case of myocarditis following the second dosage of COVID-19 vaccine. In this case, myocarditis was suspected by troponin and erythrocyte sedimentation rate (ESR) levels prior to echocardiography, which demonstrated mild pericardial effusion, mild tricuspid regurgitation, and mild asymmetric left ventricular hypertrophy. Mild to moderate symptoms of myocardial inflammation persisted throughout the patient's admission, which attributed to the clinical presentation of chest pain and palpitations. As the patient had no relevant history to account for cardiac pathologies prior to vaccination, this case report serves to further investigate the association between mRNA-derived vaccination and subsequent acute myocarditis development.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2023) conducted a case report in Acute Myocarditis (n=1). COVID-19 mRNA vaccine was evaluated on Diagnosis of acute myocarditis. A 25-year-old male developed acute myocarditis, confirmed by elevated troponin levels and echocardiographic findings, three days after receiving his final dose of a COVID-19 mRNA vaccine.
Synapse has enriched 10 related papers. Consider them for comparative context: